2 New HCV Articles at Hivandhepatitis.com

[Guest guest]

Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir

SUMMARY

New HCV antiviral drugs can interact with some antiretroviral drugs for HIV, but

others are not affected and HIV/HCV coinfected patients can be treated

successfully with minimal dose adjustments.

Early Menopause Linked to Poor Hepatitis C Treatment Response

SUMMARY

Women who enter menopause early have worse liver disease but are less likely to

achieve sustained response to interferon-based therapy for chronic hepatitis C

[Guest guest]

Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir

SUMMARY

New HCV antiviral drugs can interact with some antiretroviral drugs for HIV, but

others are not affected and HIV/HCV coinfected patients can be treated

successfully with minimal dose adjustments.

Early Menopause Linked to Poor Hepatitis C Treatment Response

SUMMARY

Women who enter menopause early have worse liver disease but are less likely to

achieve sustained response to interferon-based therapy for chronic hepatitis C

[Guest guest]

Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir

SUMMARY

New HCV antiviral drugs can interact with some antiretroviral drugs for HIV, but

others are not affected and HIV/HCV coinfected patients can be treated

successfully with minimal dose adjustments.

Early Menopause Linked to Poor Hepatitis C Treatment Response

SUMMARY

Women who enter menopause early have worse liver disease but are less likely to

achieve sustained response to interferon-based therapy for chronic hepatitis C

[Guest guest]

Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir

SUMMARY

New HCV antiviral drugs can interact with some antiretroviral drugs for HIV, but

others are not affected and HIV/HCV coinfected patients can be treated

successfully with minimal dose adjustments.

Early Menopause Linked to Poor Hepatitis C Treatment Response

SUMMARY

Women who enter menopause early have worse liver disease but are less likely to

achieve sustained response to interferon-based therapy for chronic hepatitis C